DATA GRAPHICS | Data Byte
As investor concerns ease on U.S. initiative, CFIUS returns to fore
WuXi Biologics, WuXi AppTec shares regain some ground as biomanufacturing initiative seen as limited in its reach
September 16, 2022 1:24 AM UTC
A rebound in shares of Chinese CROs and CDMOs reflected easing concerns among investors regarding the scope of a White House biomanufacturing initiative, but the roller-coaster ride for China’s biotechs may continue Friday after President Joe Biden signed an Executive Order singling out biotech for intensified foreign investment scrutiny.
Shares of four leading companies bounced back Thursday after the release of details on the manufacturing initiative, including a $1 billion investment in domestic bioindustrial manufacturing and more than $270 million earmarked to bolster the supply chain for biotechs, suggested a more limited scope than feared...